
The New England Journal of Medicine | Research & Review Articles on ...
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …
Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung …
Current Issue | New England Journal of Medicine
Nov 27, 2025 · Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 21).
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated ...
Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head …
Jun 18, 2025 · The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma …
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream ...
Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, …
Lepodisiran - The New England Journal of Medicine
Elevated lipoprotein (a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...
Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis
Mar 5, 2025 · Bacterial vaginosis affects one third of reproductive-aged women, and recurrence is common. Evidence of sexual exchange of bacterial vaginosis–associated organisms between …
Perioperative Durvalumab in Gastric and Gastroesophageal Junction ...
Jun 1, 2025 · Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates …
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal …
May 30, 2025 · Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated …